PL EN


Preferences help
enabled [disable] Abstract
Number of results
2007 | 7 | 1 | 10-18
Article title

Farmakoterapia zaburzeń ruchowych i objawów neuropsychiatrycznych w chorobie Huntingtona: systematyczny przegląd piśmiennictwa

Content
Title variants
EN
Drug treatment of moving disorders and neuropsychiatric symptoms accompanying Huntington’s disease: a systematic review
Languages of publication
EN PL
Abstracts
EN
Huntington’s disease (HD) belongs to a large group of neurodegenerative diseases caused by a genetic defect consisting in an increased number of repetitive sequences of DNA within the altered gene in the chromosome 4 encoding huntingtin. The consequence of this mutation is selective destruction of neurons mainly within the caudate nucleus, putamen, globus pallidus and also other structures, including thalamus and white matter. Apart of involuntary movements, symptoms include other neurological signs (e.g. parkinsonism), disturbed cognitive functions (dementia) and various psychiatric disorders. In spite of a significant progress in understanding HD pathogenesis, no effective cause-oriented treatment has been developed to date. Currently available therapies include attempts at correction of individual symptoms, which, as in the case of Parkinson’s disease, is handicapped by mutual interdependence of neurological and mental state, as well as by effects of administered drugs, both psychotropic and those targeted on particular neurological signs. In the paper we present an evidence based review of available modalities for symptomatic treatment of motor disorders (involuntary movements, parkinsonism, dystonias), other neurological symptoms, mental disorders (depression, psychoses) and disturbances of cognitive functions associated with HD. Separately discussed are attempts at administration of neuroprotective drugs (including creatine, unsaturated fatty acids and minocycline), which are recommended expecting to correct the natural course of the disease.
PL
Choroba Huntingtona (HD) należy do dużej grupy chorób neurozwyrodnieniowych, u których podłoża leży defekt genetyczny polegający na zwiększeniu liczby powtarzalnych sekwencji DNA w obrębie uszkodzonego genu na chromosomie 4., kodującego huntingtynę. Następstwem mutacji jest selektywne uszkodzenie neuronów dotyczące zwłaszcza jądra ogoniastego, skorupy i gałki bladej, a także innych struktur, w tym wzgórza i istoty białej. Objawy choroby obejmują poza ruchami mimowolnymi także inne objawy neurologiczne (np. parkinsonizm), zaburzenia funkcji poznawczych (otępienie) oraz różnorodne zaburzenia psychiczne. Pomimo postępów w rozumieniu etiopatogenezy choroby nie przełożyło się to, jak dotąd, na skuteczne, przyczynowe leczenie. Postępowanie obejmuje zatem próby korygowania poszczególnych objawów, co podobnie jak w chorobie Parkinsona utrudniają wzajemne zależności między stanem neurologicznym i psychicznym, oraz wpływ leków, zarówno psychotropowych, jak i celowanych na objawy neurologiczne. W artykule przedstawiamy umocowany w zasadach medycyny opartej na faktach przegląd dostępnych metod leczenia objawowego zaburzeń ruchowych (ruchy mimowolne, parkinsonizm, dystonie), innych objawów neurologicznych, zaburzeń psychicznych (depresji, psychoz) oraz zaburzeń funkcji poznawczych w przebiegu HD. Oddzielnie omawiamy próby stosowania leków o działaniu neuroprotekcyjnym (w tym kreatyny, nienasyconych kwasów tłuszczowych i minocykliny), które proponuje się w nadziei, że wpłyną korygująco na naturalny przebieg choroby.
Discipline
Year
Volume
7
Issue
1
Pages
10-18
Physical description
References
  • 1. Huntington’s Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993; 72: 971-983.
  • 2. Kokmen E., Ozekmekci S., Beard C.M. i wsp.: Incidence and prevalence of Huntington’s disease in Olmsted County, Minnesota (1950 through 1989). Arch. Neurol. 1994; 51: 696-698.
  • 3. Foroud T., Gray J., Ivashina J., Conneally P.M.: Differences in duration of Huntington’s disease based on age at onset. J. Neurol. Neurosurg. Psychiatry 1999; 66: 52-56.
  • 4. Ho A.K., Robbins A.O.G., Barker R.A.: Huntington’s disease patients have selective problems with insight. Mov. Disord. 2006; 21: 385-389.
  • 5. Snowden J.S., Craufurd D., Griffiths H.L., Neary D.: Awareness of involuntary movements in Huntington’s disease. Arch. Neurol. 1998; 55: 801-805.
  • 6. Quinn N., Marsden C.D.: A double blind trial of sulpiride in Huntington’s disease and tardive dyskinesia. J. Neurol. Neurosurg. Psychiatry 1984; 47: 844-847.
  • 7. Roos R.A., Buruma O.J., Bruyn G.W i wsp.: Tiapride in the treatment of Huntington’s chorea. Acta Neurol. Scand. 1982; 65: 45-50.
  • 8. Deroover J., Baro F., Bourguignon R.P., Smets P: Tiapride versus placebo: a double-blind comparative study in the management of Huntington’s chorea. Curr. Med. Res. Opin. 1984; 9: 329-338.
  • 9. Barr A.N., Fischer J.H., Koller WC. i wsp.: Serum halo-peridol concentration and choreiform movements in Huntington’s disease. Neurology 1988; 38: 84-88.
  • 10. Caine E.D., Polinsky R.J., Kartzinel R., Ebert M.H.: The trial use of clozapine for abnormal involuntary movement disorders. Am. J. Psychiatry 1979; 136: 317-320.
  • 11. van Vugt J.P., Siesling S., Vergeer M. i wsp.: Clozapine versus placebo in Huntington’s disease: a double blind randomised comparative study. J. Neurol. Neurosurg. Psychiatry 1997; 63: 35-39.
  • 12. Bonelli R.M., Mahnert F.A., Niederwieser G.: Olanzapine for Huntington’s disease: an open label study. Clin. Neuropharmacol. 2002; 25: 263-265.
  • 13. Paleacu D., Anca M., Giladi N.: Olanzapine in Huntington’s disease. Acta Neurol. Scand. 2002; 105: 441-444.
  • 14. Squitieri F., Cannella M., Piorcellini A. i wsp.: Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol. Behav. Neurol. 2001: 14: 69-72.
  • 15. Verhagen Metman L., Morris M.J., Farmer C. i wsp.: Huntington’s disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002; 59: 694-699.
  • 16. Lucetti C., Del Dotto P, Gambaccini G. i wsp.: IV amantadine improves chorea in Huntington’s disease: an acute randomized, controlled study. Neurology 2003; 60:1995-1997.
  • 17. O’Suilleabhain P., Dewey RB Jr: A randomized trial of amantadine in Huntington disease. Arch. Neurol. 2003; 60: 996-998.
  • 18. Heckmann J.M., Legg P., Sklar D. i wsp.: IV amantadine improves chorea in Huntington’s disease: an acute randomized, controlled study. Neurology 2004; 63: 597-598.
  • 19. Rosas H.D., Koroshetz WJ., Jenkins B.G. i wsp.: Riluzole therapy in Huntington’s disease (HD). Mov. Disord. 1999; 14: 326-330.
  • 20. Seppi K., Mueller J., Bodner T. i wsp.: Riluzole in Huntington’s disease (HD): an open label study with one year follow up. J. Neurol. 2001; 248: 866-869.
  • 21. Huntington Study Group: Dosage effects of riluzole in Huntington’s disease: a multicenter placebo-controlled study. Neurology 2003; 61: 1551-1556.
  • 22. Kieburtz K., Feigin A., McDermott M. i wsp.: A controlled trial of remacemide hydrochloride in Huntington’s disease. Mov. Disord. 1996; 11: 273-277.
  • 23. Huntington Study Group: A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology 2001; 57: 397-404.
  • 24. Albanese A., Cassetta E., Carretta D. i wsp.: Acute challenge with apomorphine in Huntington’s disease: a doubleblind study. Clin. Neuropharmacol. 1995; 18: 427-434.
  • 25. Frattola L., Albiazzati M.G., Spano P.F., Trabucchi M.: Treatment of Huntington’s chorea with bromocriptine. Acta Neurol. Scand. 1977; 56: 37-45.
  • 26. Feigin A., Kieburtz K., Bordwell K. i wsp.: Functional decline in Huntington’s disease. Mov. Disord. 1995; 10: 211-214.
  • 27. Nash M.C., Ferrell R.B., Lombardo M.A., Williams R.B.: Treatment of bruxism in Huntington’s disease with botulinum toxin. J. Neuropsychiatry Clin. Neurosci. 2004; 16: 381-382.
  • 28. Koller W.C., Trimble J.: The gait abnormality of Huntington’s disease. Neurology 1985; 35: 1450-1454.
  • 29. Mayberg H.S., Starkstein S.E., Peyser C.E. i wsp.: Paralimbic frontal lobe hypometabolism in depression associated with Huntington’s disease. Neurology 1992; 42: 1791-1797.
  • 30. Sobów T, Liberski P.P.: Choroby wywołane zmianą liczby powtarzalnych sekwencji DNA. W: Kozubski W., Liberski P.P. (red.): Choroby układu nerwowego. PZWL, Warszawa 2004: 271-280.
  • 31. Madhusoodanan S., Brenner R.: Use of risperidone in psychosis associated with Huntington’s disease. Am. J. Geriatr. Psychiatry 1998; 6: 347-349.
  • 32. Erdemoglu A.K., Boratav C.: Risperidone in chorea and psychosis of Huntington’s disease. Eur. J. Neurol. 2002; 9: 182-183.
  • 33. Bonelli R.M., Niederwieser G.: Quetiapine in Huntington’s disease: a first case report. J. Neurol. 2002; 249:1114-1115.
  • 34. Seitz D.P, Millson R.C.: Quetiapine in the management of psychosis secondary to Huntington’s disease: a case report. Can. J. Psychiatry 2004; 49: 413.
  • 35. Alpay M., Koroshetz WJ.: Quetiapine in the treatment of behavioral disturbances in patients with Huntington’s disease. Psychosomatics 2006; 47: 70-72.
  • 36. Leonard D.P., Kidson M.A., Brown J.G. i wsp.: A double blind trial of lithium carbonate and haloperidol in Huntington’s chorea. Aust. N.Z. J. Psychiatry 1975; 9: 115-118.
  • 37. Grove VE. Jr, Quintanilla J., DeVaney G.T.: Improvement of Huntington’s disease with olanzapine and valproate. N. Engl. J. Med. 2000; 343: 973-974.
  • 38. Fernandez H.H., Friedman J.H., Grace J., Beason-Hazen S.: Donepezil for Huntington’s disease. Mov. Disord. 2000: 15: 173-176.
  • 39. de TommasoM., Specchio N., SciruicchioV iwsp.: Effects of rivastigmine on motor and cognitive impairment in Huntington’s disease. Mov. Disord. 2004; 19: 1516-1518.
  • 40. Puri B.K., Bydder G.M., Counsell S.J. i wsp.: MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002; 13: 123-126.
  • 41. Bonelli R.M., Heuberger C., Reisecker F.: Minocycline for Huntington’s disease: an open label study. Neurology 2003; 60: 883-884.
  • 42. Ferrante R.J., Andreassen O.A., Jenkins B.G. i wsp.: Neuroprotective effects of creatine in a transgenic mouse model of Huntington’s disease. J. Neurosci. 2000; 20: 4389-4397.
  • 43. Andreassen O.A., Dedeoglu A., Ferrante R.J. i wsp.: Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington’s disease. Neurobiol. Dis. 2001; 8: 479-491.
  • 44. Dedeoglu A., Kubilus J.K., Yang L. i wsp.: Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington’s disease transgenic mice. J. Neurochem. 2003; 85: 1359-1367.
  • 45. Tabrizi S.J., Blamire A.M., Manners D.N. i wsp.: High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 2005; 64: 1655-1656.
  • 46. Bender A., Auer D.P., Merl T. i wsp.: Creatine supplementation lowers brain glutamate levels in Huntington’s disease. J. Neurol. 2005; 252: 36-41.
  • 47. Verbessem P., Lemiere J., Eijnde B.O. i wsp.: Creatine supplementation in Huntington’s disease: a placebo-controlled pilot trial. Neurology 2003; 61: 925-930.
  • 48. Vaddadi K.S., Soosai E., Chiu E., Dingjan P: A randomised, placebo-controlled, double blind study of treatment of Huntington’s disease with unsaturated fatty acids. Neuroreport 2002; 13: 29-33.
  • 49. Puri B.K., Leavitt B.R., Hayden M.R. i wsp.: Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005; 65: 286-292.
  • 50. Berger A.: Minocycline slows progress of Huntington’s disease in mice. BMJ 2000; 321: 70.
  • 51. Chen M., Ona V.O., Li M. i wsp.: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 2000; 6: 797-801.
  • 52. Bonelli R.M., Hodl A.K., Hofmann P., Kapfhammer H.P.: Neuroprotection in Huntington’s disease: a 2-year study on minocycline. Int. Clin. Psychopharmacol. 2004; 19: 337-342.
  • 53. Huntington Study Group: Minocycline safety and tolera-bility in Huntington disease. Neurology 2004; 63: 547-549.
  • 54. Peyser C.E., Folstein M., Chase GA. i wsp.: Trial of d-alpha-tocopherol in Huntington’s disease. Am. J. Psychiatry 1995; 152: 1771-1775.
  • 55. Ranen N.G., Peyser C.E., Coyle J.T. i wsp.: A controlled trial of idebenone in Huntington’s disease. Mov. Disord. 1996; 11:549-554.
  • 56. Shoulson I., Odoroff C., Oakes D. i wsp.: A controlled clinical trial of baclofen as protective therapy in early Huntington’s disease. Ann. Neurol. 1989; 25: 252-259.
  • 57. Kremer B., Clark C.M., Almqvist E.W i wsp.: Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 1999; 53:1000-1011.
  • 58. Sadri-Vakili G., Cha J.H.: Histone deacetylase inhibitors: a novel therapeutic approach to Huntington’s disease (complex mechanism of neuronal death). Curr. Alzheimer Res. 2006; 3: 403-408.
  • 59. Skogen M., Roth J., Yerkes S. i wsp.: Short G-rich oligonucleotides as a potential therapeutic for Huntington’s disease. BMC Neurosci. 2006; 7: 65.
  • 60. Chouza C., Romero S., Lorenzo J. i wsp.: Clinical trial of tiapride in patients with dyskinesia. Sem. Hop. 1982; 58: 725-733.
  • 61. Terrence C.F.: Fluphenazine decanoate in the treatment of chorea: a double-blind study. Curr. Ther. Res. Clin. Exp. 1976; 20: 177-183.
  • 62. Fahn S.: Treatment of choreic movements with perphenazine. Dis. Nerv. Syst. 1972; 33: 653-658.
  • 63. Gimenez-Roldan S., Mateo D.: Huntington disease: tetra-benazine compared to haloperidol in the reduction of involuntary movements. Neurologia 1989; 4: 282-287.
  • 64. Girotti F., Carella F., Scigliano G. i wsp.: Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington’s disease. J. Neurol. Neuro-surg. Psychiatry 1984; 47: 848-852.
  • 65. Bobon D.P., Devroye A., Goffioul L., Pinchard A.: Pimozide: 16 months of follow-up. Acta Neurol. Psychiatr. Belg. 1968; 68: 887-894.
  • 66. Arena R., Iudice A., Virgili P. i wsp.: Huntington’s disease: clinical effects of a short-term treatment with pimozide. Adv. Biochem. Psychopharmacol. 1980; 24: 573-575.
  • 67. Quinn N., Marsden C.D.: Tiapride in 12 Huntington’s disease patients. J. Neurol. Neurosurg. Psychiatry 1985; 48:292.
  • 68. Mattsson B., Boman K.: Buronil in Huntington’s chorea. Lancet 1974; 2: 1323.
  • 69. Bonuccelli U., Ceravolo R., Maremmani C. i wsp.: Clozapine in Huntington’s chorea. Neurology 1994; 44: 821-823.
  • 70. Colosimo C., Cassetta E., Bentivoglio A.R., Albanese A.: Clozapine in Huntington’s disease. Neurology 1995; 45: 1023-1024.
  • 71. Whittier J.R., Korenyi C.: Effect of oral fluphenazine on Huntington’s chorea. Int. J. Neuropsychiatry 1968; 4: 1-3.
  • 72. Siegmund R., Schmeisser G., Heidrich R.: Therapeutic experiences in the treatment of hyperkineses with the neuroleptic pimozide (Antalon, Orap) in the frame of Huntington chorea. Psychiatr. Neurol. Med. Psychol. (Leipz.) 1982; 34: 307-308.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-4caf2ad3-7053-4a12-9d38-4d44119a85aa
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.